Compare D Wave Quantum Inc (QBTS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

QBTS trades at $17.67, up 6.57% in the last session, but remains down 33% year-to-date. The stock shows a bearish technical trend with key support at $17 and resistance at $18. Fundamentally, the company reported a net loss of $355.06 million on $24.59 million in revenue for 2025, with a negative net income margin of -2,001.59% in 2026. Recent positive news includes a $100 million funding agreement with the U.S. Department of Commerce under the CHIPS Act, announced on September 8, 2026.

Despite unanimous analyst buy ratings and a $37.00 consensus price target, significant execution risks persist. High cash burn, negative profitability, and ongoing SEC investigations pose challenges. The stock's upside depends on successful commercialization of quantum technology and effective use of government funding, but near-term volatility is expected amid sector-wide pressures and macroeconomic uncertainty.

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.